Literature DB >> 33012318

Biologics for the Treatment of Allergic Rhinitis, Chronic Rhinosinusitis, and Nasal Polyposis.

William Eschenbacher1, Matthew Straesser1, Alice Knoeddler1, Rung-Chi Li1, Larry Borish2.   

Abstract

Allergic rhinitis (AR), most presentations of nasal polyposis (NP), and many presentations of chronic rhinosinusitis are type 2high disorders characterized by expression of interleukin (IL)-4, IL-5, and IL-13. Neutralization of IgE with anti-IgE (omalizumab) has proven efficacy in AR. Similarly, in addition to anti-IgE, blockade of IL-5/IL-5 (mepolizumab, reslizumab, benralizumab) and dual blockade of IL-4 and IL-13 with anti-IL-4R (dupilumab) have demonstrated efficacy in NP. However, these agents are expensive and future studies are essential to evaluate cost effectiveness in comparison with current medical and surgical therapies. This article reviews biologics as potential interventions in AR, chronic rhinosinusitis, and NP.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Allergic rhinitis; Chronic rhinosinusitis; Eosinophils; IgE; Interleukins; Nasal polyposis; Type 2 inflammation

Year:  2020        PMID： 33012318      PMCID： PMC7539135          DOI： 10.1016/j.iac.2020.06.001

Source DB:  PubMed          Journal:  Immunol Allergy Clin North Am        ISSN： 0889-8561            Impact factor:   3.479


  21 in total

Review 1.  The pharmacological basis of anti-IgE therapy.

Authors:  T W Chang
Journal:  Nat Biotechnol       Date:  2000-02       Impact factor: 54.908

2.  Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma.

Authors:  Philippe Gevaert; Lien Calus; Thibaut Van Zele; Katrien Blomme; Natalie De Ruyck; Wouter Bauters; Peter Hellings; Guy Brusselle; Dirk De Bacquer; Paul van Cauwenberge; Claus Bachert
Journal:  J Allergy Clin Immunol       Date:  2012-09-27       Impact factor: 10.793

3.  Clinical Efficacy and Safety of Omalizumab in the Treatment of Allergic Rhinitis: A Systematic Review and Meta-analysis of Randomized Clinical Trials.

Authors:  Chenjie Yu; Kaijian Wang; Xinyan Cui; Ling Lu; Jianfei Dong; Maohua Wang; Xia Gao
Journal:  Am J Rhinol Allergy       Date:  2019-11-01       Impact factor: 2.467

4.  Total and specific IgE in nasal polyps is related to local eosinophilic inflammation.

Authors:  C Bachert; P Gevaert; G Holtappels; S G Johansson; P van Cauwenberge
Journal:  J Allergy Clin Immunol       Date:  2001-04       Impact factor: 10.793

5.  Allergic conversion of protective mucosal immunity against nasal bacteria in patients with chronic rhinosinusitis with nasal polyposis.

Authors:  Kazuya Takeda; Shuhei Sakakibara; Kazuo Yamashita; Daisuke Motooka; Shota Nakamura; Marwa Ali El Hussien; Jun Katayama; Yohei Maeda; Masanobu Nakata; Shigeyuki Hamada; Daron M Standley; Masaki Hayama; Takashi Shikina; Hidenori Inohara; Hitoshi Kikutani
Journal:  J Allergy Clin Immunol       Date:  2018-07-25       Impact factor: 10.793

6.  Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.

Authors:  Claus Bachert; Joseph K Han; Martin Desrosiers; Peter W Hellings; Nikhil Amin; Stella E Lee; Joaquim Mullol; Leon S Greos; John V Bosso; Tanya M Laidlaw; Anders U Cervin; Jorge F Maspero; Claire Hopkins; Heidi Olze; G Walter Canonica; Pierluigi Paggiaro; Seong H Cho; Wytske J Fokkens; Shigeharu Fujieda; Mei Zhang; Xin Lu; Chunpeng Fan; Steven Draikiwicz; Siddhesh A Kamat; Asif Khan; Gianluca Pirozzi; Naimish Patel; Neil M H Graham; Marcella Ruddy; Heribert Staudinger; David Weinreich; Neil Stahl; George D Yancopoulos; Leda P Mannent
Journal:  Lancet       Date:  2019-09-19       Impact factor: 79.321

7.  Diversity of TH cytokine profiles in patients with chronic rhinosinusitis: A multicenter study in Europe, Asia, and Oceania.

Authors:  Xiangdong Wang; Nan Zhang; Mingyu Bo; Gabriele Holtappels; Ming Zheng; Hongfei Lou; Hong Wang; Luo Zhang; Claus Bachert
Journal:  J Allergy Clin Immunol       Date:  2016-07-15       Impact factor: 10.793

8.  Elevated total serum IgE in nonatopic patients with aspirin-exacerbated respiratory disease.

Authors:  Christina B Johns; Tanya M Laidlaw
Journal:  Am J Rhinol Allergy       Date:  2014 Jul-Aug       Impact factor: 2.467

9.  Omalizumab treats chronic rhinosinusitis with nasal polyps and asthma together-a real life study.

Authors:  T Bidder; J Sahota; C Rennie; V J Lund; D S Robinson; H H Kariyawasam
Journal:  Rhinology       Date:  2018-03-01       Impact factor: 3.681

10.  Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial.

Authors:  Claus Bachert; Ana R Sousa; Valerie J Lund; Glenis K Scadding; Philippe Gevaert; Shuaib Nasser; Stephen R Durham; Marjolein E Cornet; Harsha H Kariyawasam; Jane Gilbert; Daren Austin; Aoife C Maxwell; Richard P Marshall; Wytske J Fokkens
Journal:  J Allergy Clin Immunol       Date:  2017-07-04       Impact factor: 10.793
View more
  4 in total

Review 1.  Therapeutic Strategies of Biologics in Chronic Rhinosinusitis: Current Options and Future Targets.

Authors:  Junhu Tai; Munsoo Han; Tae Hoon Kim
Journal:  Int J Mol Sci       Date:  2022-05-15       Impact factor: 6.208

2.  Influences of miR-378a-3p on the Pathogenesis of Allergic Rhinitis via GzmB-Mediated Inflammatory Reaction.

Authors:  Xuping Wang; Haiqing Zhang; Long Du; Lian Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-29       Impact factor: 2.650

3.  Activation of STAT6 by intranasal allergens correlated with the development of eosinophilic chronic rhinosinusitis in a mouse model.

Authors:  Hongqi Wei; Longjiang Xu; Peng Sun; Hongyu Xing; Zhengwen Zhu; Jisheng Liu
Journal:  Int J Immunopathol Pharmacol       Date:  2022 Jan-Dec       Impact factor: 3.298

4.  An Analysis of Biologic Therapies in Patients With Asthma and Chronic Rhinosinusitis.

Authors:  Mitchell R Gore; Ethan Fung; Michael Tao
Journal:  Cureus       Date:  2022-10-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.